Known as “3TR” Taxonomy, Treatments, Targets and Remission is funded by the European Union (EU) Innovative Medicines Initiative for the next seven years. With 80 million Euro commitment, a prominent group of collaborators will use genomic and clinical data from over 50,000 patients in 50 clinical trials with the goal of identifying molecules that can predict whether patients will respond to treatments in several autoimmune conditions.
Unprecedented Public-Private Research
3TR represents what some have called an unprecedented public-private research endeavor in Europe bringing together 69 partners including academic medical centers, industry, patient organizations and others covering 15 European nations. This interdisciplinary consortium seeks to explore the mechanisms of response and non-response to treatment within and across seven different immune-mediated diseases.
Eucrice, the European Research and Project Office GmbH, will manage 3TR. Eucrice offers comprehensive support services for the planning, initiation, and implementation of international collaborative research and innovation projects with competencies in project management, portfolio management, project planning, proposal writing and much more.
3TR will seek to uncover predictive capabilities in the following autoimmune conditions: multiple sclerosis, inflammatory bowel disease, systemic lupus erythematosus, asthma, chronic obstructive pulmonary disease, and rheumatoid arthritis. Physicians are not certain how well a treatment will work with each individual autoimmune patient today. The 3TR project seeks to transform these uncertainties over time by leveraging advanced techniques such as genomics and transcriptomics. The ultimate goal is to help physicians prescribe the most effective treatments to the patient.
A Systems Approach to Autoimmune Disorder
The targeted autoimmune conditions all have underlying biological underpinnings—for example, autoimmune conditions such as lupus and asthma may have common biomarkers. This intensive effort will help researchers pool their knowledge and accelerate research into more precise treatments.
Who is Participating in 3TR?
69 organizations prestigious organizations (partners) are participating in the European research affair. In addition to some of the world’s largest pharmaceutical companies and most elite academic research centers. We offer a list here. The partners met recently in Granada, Spain to kick the initiative off.
Call to Action: Interested in learning more about 3TR? Their lead contact is Professor Marta E Alarcon-Riquelme, GENYO centre at the Fundación Pública Andaluza Progreso y Salud (FPS); Phone: +34 (958) 715 500-113